Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen to Address NICE's Concerns Following Another English Funding No For Spravato

Executive Summary

UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.

You may also be interested in...



Janssen May Challenge English Funding Rejection For Depression Nasal Spray

Health technology assessment body NICE has now rejected Spravato for the third time, saying it has concerns over the clinical evidence and economic model for the drug, for treating adults with major depression that is resistant to treatment.

Same Price & Trial Data: Scotland OKs Spravato Funding After England Says No

Discrepancy in access to Janssen’s antidepressant nasal spray between patients in Scotland and those in England and the rest of the UK may be due to the differences in methodologies and approaches used by the health technology assessment bodies.

Keeping Track: Four Novel Agents Clear US FDA, Including Evrysdi, Blenrep

The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel